How Genomics Is Personalizing Drug Discovery - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

How Genomics Is Personalizing Drug Discovery

Regeneron Genetics Center’s Luca Lotta explains how population-scale genetic evidence can reveal more promising drug targets and open new possibilities for disease prevention

  • By

  • Mouj Hijazi

  • October 20, 2026

  • 8 min

Share

  • 1

    Regeneron Genetics Center studies deidentified genomic and health data from more than 3 million people to identify genes and pathways associated with disease and protection.

  • 2

    Historically, drug targets supported by human genetics have been 2 to 3 times more likely to succeed and eventually receive approval.

  • 3

    Natural genetic variants that activate or inactivate pathways can help researchers anticipate the effects of modifying those pathways with medicines.

  • 4

    In a study of more than 1 million DNA samples, rare FNIP1 mutations were associated with favorable metabolic measures and an approximately 60% lower risk of cardiometabolic disease.

  • 5

    Lotta said genomic discoveries may help explain individual differences in disease predisposition, while personalized medicine remains at an early stage.

Original Source(s)

How Genomics Is Personalizing Drug Discovery

  • by Mouj Hijazi

  • October 20, 2026

Related Content

Depression, anxiety symptoms may be common in T1D

National survey data show a greater mental health symptom burden among adults with type 1 diabetes vs. those with type 2 diabetes or no diabetes.

PFAS Linked to Lipid Changes in Children

Researchers examine links between widespread exposure and metabolic health markers

  • October 20, 2026

  • 3 min
Early Adoption and Diffusion of Oral Semaglutide in US Adults With Obesity